BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock
BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, recently sold 6,845 shares of the company’s common stock for $7,426 to cover taxes related to vested restricted stock units. This transaction, executed under a Rule 10b5-1 trading plan, occurred after he acquired 17,500 shares through RSU vesting earlier in May. Following these events, Yocca directly holds 26,175 shares.
BioXcel Therapeutics (BTAI) CEO sells shares to cover RSU tax obligations
BioXcel Therapeutics CEO Vimal Mehta reported exercising 49,758 Restricted Stock Units (RSUs) and subsequently selling 19,419 common shares at a weighted average price of $1.087 to cover tax obligations from the RSU vesting. This sale was conducted under a Rule 10b5-1 trading plan. After the transaction, Mehta directly holds 69,598 common shares, with additional indirect holdings through BioXcel LLC and his spouse.
Baxter International Stock 5-Day Winning Spree: Stock Climbs 11%
The article reports that Baxter International (BAX) stock has experienced a 5-day winning streak, resulting in an 11% climb. The brief content available only states this performance without further details or analysis. The full article content is not provided, showing only site navigation and disclaimers.
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
This article identifies top gapping stocks on Tuesday, categorizing them into "gap up" and "gap down" groups. It provides specific details for each stock listed, including percentage change, gap percentage, stock price, and relevant news like earnings releases or press statements.
(BBC) as a Liquidity Pulse for Institutional Tactics
This article from Stock Traders Daily analyzes Virtus Lifesci Biotech Clinical Trials Etf (NYSE: BBC), noting weak near and mid-term sentiment but a strong long-term outlook. It provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The piece suggests elevated downside risk due to a lack of additional long-term support signals.
(ATRC) and the Role of Price-Sensitive Allocations
Atricure Inc. (NASDAQ: ATRC) shows strong near-term sentiment with neutral mid and long-term outlooks, featuring a mid-channel oscillation pattern. AI models suggest specific institutional trading strategies, including long, breakout, and short positions, with an exceptional 65.4:1 risk-reward setup targeting a 19.5% gain versus 0.3% risk. The analysis provides multi-timeframe signal insights, including support and resistance levels for various holding periods.
Biogen Inc. (NASDAQ: BIIB) Navigates Alzheimer’s Drug Trajectory After Leqembi Updates
Biogen (NASDAQ: BIIB) is managing expectations for its Alzheimer’s drug Leqembi, which received full FDA approval but has seen slower-than-anticipated commercial uptake. Despite challenges in patient identification and reimbursement, Biogen anticipates accelerated adoption as infrastructure matures. The company is refocusing its pipeline on neuroscience and rare diseases, while analysts remain mixed on the stock's future, with upcoming quarterly earnings and Leqembi sales data being key catalysts.
Gilead Sciences Inc. (NASDAQ: GILD) Holds Steady as HIV and Oncology Portfolio Drives Income
Gilead Sciences Inc. (NASDAQ: GILD) is demonstrating stability due to its strong HIV and growing oncology portfolios. The company's consistent cash generation, attractive dividend yield, and share repurchases make it a reliable income-oriented investment, especially during volatile market conditions. Analysts generally view GILD as a hold or buy, focusing on the growth of its oncology drug Trodelvy and the sustained performance of its HIV franchise.
Director at TransMedics (TMDX) receives 2,922 RSU equity grant, holds 5,788 shares
TransMedics Group, Inc. director Edward M. Basile received an equity grant of 2,922 restricted stock units (RSUs) at no cash cost. This grant increased his direct holdings to 5,788 shares of the company's common stock. The transaction, reported in a Form 4 SEC filing, represents a form of equity compensation rather than a cash purchase or open-market transaction.
Takeda Vows Appeal of $885M Jury Verdict in ‘Pay-for-Delay’ Antitrust Case
A jury awarded nearly $885 million in damages against Takeda Pharmaceutical in a "pay-for-delay" antitrust case concerning its constipation drug Amitiza. Pharmacies and wholesalers claimed Takeda illegally delayed generic competition. Takeda plans to appeal the verdict, citing "evidentiary and legal errors," and if upheld, the damages would be automatically tripled to over $2.6 billion under federal antitrust law.
Moderna Inc. (NASDAQ: MRNA) Stock Under Pressure as mRNA Platform Seeks New Applications
Moderna Inc. (NASDAQ: MRNA) continues to face significant investor pressure in 2026 as its transition from COVID-19 vaccine revenue to new mRNA applications like flu, RSV, and cancer vaccines has been slower than anticipated. Despite a substantial cash position and aggressive cost management, investor sentiment remains cautious due to uncertainty regarding the commercial scale and timeline for new products. Key pipeline readouts, particularly from its personalized cancer vaccine program with Merck, are crucial for demonstrating a clear path to sustainable revenue and improving stock volatility.
Amgen Inc. (NASDAQ: AMGN) Stock Trades Near $330 as Japan Drug Safety Crisis Raises Concerns
Amgen Inc. (NASDAQ: AMGN) stock was trading near $330 after a report revealed that at least 20 people in Japan died and 22 others developed liver injuries after taking Amgen's rare disease drug. Japanese seller Kissei Pharmaceutical advised doctors to stop prescribing the drug. This news raises concerns about regulatory and reputational implications for Amgen, even as the company's Q1 2026 results showed strong growth for other products and an anticipated CFO transition occurred.
Insider Sell Alert: Daveen Chopra Sells Shares of Edwards Lifesc
Daveen Chopra, CVP, TMTT & Surgical at Edwards Lifesciences Corp (EW), sold 1,500 shares of the company on May 22, 2026. This transaction brings Chopra's total ownership to 44,324 shares. Over the past year, Chopra has sold 6,000 shares, and there have been 32 insider sells with no buys at Edwards Lifesciences Corp during the same period. The stock is currently trading at $84.6, with a market cap of $49.392 billion, and is considered fairly valued according to its GuruFocus Value.
Bronstein, Gewirtz & Grossman, LLC Is Investigating TriSalus Life Sciences, Inc. (RLSI) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TriSalus Life Sciences, Inc. (NASDAQ:RLSI). The investigation follows TriSalus's report of a decline in Q1 revenue and a cut to full-year revenue guidance, attributed to lower Q1 revenues and delayed FDA clearance for TriNav Advance. The firm encourages stockholders to connect to assist with the investigation into the company's stock drop.
Intuitive Surgical (ISRG) EVP Brosius sells 36 shares in planned trades
Intuitive Surgical (ISRG) Executive Vice President Mark Brosius sold a total of 36 shares of company stock in two separate open-market transactions on May 21 and May 22, 2026. These sales, executed under a Rule 10b5-1 trading plan, amounted to approximately $15,945. Following these transactions, Brosius directly holds 1,523 shares of Intuitive Surgical Common Stock.
Theravance Biopharma (TBPH) SVP has 8,829 shares withheld for RSU tax
Theravance Biopharma (TBPH) SVP Brett A. Grimaud had 8,829 ordinary shares withheld at $16.55 per share to cover taxes on vested restricted stock units. This was a tax-withholding transaction with the company, not an open-market sale. After this transaction, Grimaud directly holds 363,120 ordinary shares.
Theravance Biopharma (TBPH) CEO has shares withheld to cover RSU taxes
Theravance Biopharma CEO Rick E. Winningham reported a routine tax-related share withholding on May 20, 2026. A total of 20,038 Ordinary Shares were withheld at $16.55 per share to cover tax obligations from vesting restricted stock units. This transaction was directly with the company and not an open market sale, leaving Winningham with 1,631,056 directly held Ordinary Shares, along with indirect holdings.
Telomir (NASDAQ: TELO) CEO reshapes 4M+ options at lower $1.30 strike
Telomir Pharmaceuticals, Inc. CEO and Chairman Erez Aminov recently modified his stock option awards. He canceled previously granted options totaling nearly 4 million shares at higher exercise prices ($2.10 and $5.02) and received new, fully exercisable options for the same number of shares at a reduced exercise price of $1.30. These new options are set to expire in 2036, and the filing indicated no open-market purchases or sales of common stock by Aminov.
Telomir Pharmaceuticals (TELO) director resets 25K stock options terms
Telomir Pharmaceuticals director Matthew Paul Del Giudice restructured his stock options by canceling 25,000 existing incentive stock options with a $5.02 exercise price and an August 27, 2034 expiration date. He received a new grant of 25,000 incentive stock options at a lower exercise price of $1.30 per share and a later expiration date of May 21, 2036. This transaction resulted in no net change to the total number of options held, only an adjustment of their terms.
Telomir Pharmaceuticals (TELO) director swaps 25K options for lower $1.30 strike
Telomir Pharmaceuticals director Whalen Matthew Pratt restructured 25,000 incentive stock options, canceling those with a $5.02 exercise price for new ones at a lower $1.30 exercise price, expiring in 2036. This transaction maintains his total option holdings at 25,000 fully exercisable shares. The Form 4 filing indicates a change in his compensation structure rather than direct market trades.
Bio-Rad Laboratories, Inc. Class B Trade Ideas — BOATS:BIO.B
This article aggregates trade ideas for Bio-Rad Laboratories, Inc. (BIO.B) from various traders on TradingView. Ideas range from long positions based on fundamental analysis and technical indicators like the 100 EMA and RSI, to short positions anticipated after a technical break. ValuEngine also upgraded its rating for BIO.B to a BUY.
[Form 4/A] Alkermes plc. Amended Insider Trading Activity
This article reports an amended insider trading activity for Alkermes plc (ALKS), detailing equity awards granted to director Richard Gaynor. The amendment clarifies the vesting terms for 5,409 restricted stock units and 11,538 non-qualified stock options, which were previously misreported. The awards vest on the earlier of one year from the grant date or the company's next annual general meeting.
[Form 4] Alkermes plc. Insider Trading Activity
Alkermes plc. director Cato T. Laurencin reported routine equity compensation activity, including the receipt of 5,409 restricted stock units (RSUs) and 11,538 non-qualified stock options with a $36.98 exercise price. Following this, 6,142 RSUs were converted into ordinary shares, and 1,475 shares were withheld for taxes, resulting in Laurencin directly holding 35,244 ordinary shares. The Form 4 filing details these transactions and Laurencin's holdings after the reported activities.
Alkermes (ALKS) director gets new RSUs, options and tax withholding
Alkermes plc director Christopher I. Wright reported equity transactions, including the exercise of 6,142 restricted stock units and the withholding of 1,475 shares for tax obligations. He also received new awards consisting of 5,409 restricted stock units and 11,538 non-qualified stock options with a $36.98 exercise price. Following these transactions, Wright directly holds 27,680 ordinary shares in Alkermes.
Align Technology to open manufacturing facility in India
Align Technology (NASDAQ:ALGN) plans to invest approximately $200 million over several years to open its fourth global manufacturing facility in Hyderabad, India by 2027. This move is expected to create over 300 jobs and further expand the company's presence in the Asia-Pacific region. The investment aligns with Align's strong financial position and follows recent positive earnings reports and analyst endorsements.
BioXcel Therapeutics chief legal officer sells $7,111 in stock
Javier Rodriguez, Chief Legal Officer of BioXcel Therapeutics, recently sold $7,111 worth of company stock to cover taxes related to restricted stock unit vesting. The sale involved 6,560 shares at an average price of $1.084. Currently, BioXcel Therapeutics (BTAI) stock is trading near its 52-week low.
BioXcel Therapeutics CEO Mehta sells $21,108 in company stock
BioXcel Therapeutics CEO Vimal Mehta sold 19,419 shares of the company's common stock for a total of $21,108 on May 20, 2026, at an average price of $1.087 per share. This sale followed the vesting of restricted stock units and was conducted under a Rule 10b5-1 trading plan to cover tax obligations. The company's financial health is rated "WEAK" by InvestingPro, and shares are down 29% year-to-date.
Belite Bio, Inc 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:BLTE) 2026-05-22
Belite Bio, Inc (NASDAQ:BLTE) released its Q1 2026 earnings call presentation, reporting an EPS of -$0.68, missing estimates by $0.04, and revenue of $0.00, which beat estimates by $0.00. The company published a slide deck in conjunction with the earnings call, prepared by Seeking Alpha's transcripts team.
Securities Fraud Investigation Into GE HealthCare Technologies In
The Law Offices of Frank R. Cruz are continuing their securities fraud investigation into GE HealthCare Technologies Inc. (NASDAQ: GEHC) following a significant stock price drop. This investigation concerns potential violations of federal securities laws after the company reported lower-than-expected adjusted earnings per share for Q1 2026 and cut its full-year guidance, citing recalls and supplier issues. Shareholders who lost money are urged to contact the firm to inquire about pursuing a claim.
[Form 4] ALIGN TECHNOLOGY INC Insider Trading Activity
This article details an insider trading activity for ALIGN TECHNOLOGY INC (ALGN) reported by director Myong Anne. The Form 4 filing shows that 1,745 Restricted Stock Units (RSUs) granted in May 2025 vested and were settled in common stock, increasing her direct holdings to 9,830 shares. Additionally, she received a new grant of 1,836 RSUs set to vest by May 2027 or the next annual stockholder meeting.
Precigen (PGEN): The Best Penny Stock to Buy for Long Term
Precigen (NASDAQ:PGEN) is highlighted as a top long-term penny stock, following positive Q1 earnings and increased price targets from H.C. Wainwright and Citizens. The company reported strong PAPZIMEOS sales exceeding guidance, and is expanding its commercialization efforts while continuing development of PRGN-2009 for HPV-associated cancers. Management expects current cash and PAPZIMEOS sales to fund operations to cash flow break-even by the end of 2026.
Virax Biolabs Calls June 5 EGM to Approve Reverse Share Split and Charter Amendments
Virax Biolabs Group Ltd. (VRAX) will hold an Extraordinary General Meeting (EGM) on June 5, 2026, for shareholders to vote on a significant reverse share consolidation, with a proposed ratio between 10-for-1 and 30-for-1. The company's board has unanimously recommended approval of these proposals, which also include related charter amendments, to restructure its capital base and potentially impact its share count and trading price. Virax Biolabs, a Nasdaq-listed biotechnology and diagnostics company, currently has a stock rating of Buy with a $1.00 price target from the most recent analyst forecast.
Axsome Therapeutics stock hits all-time high at 236.84 USD By Investing.com
Axsome Therapeutics (NASDAQ: AXSM) stock reached an all-time high of $236.84, trading within 1% of its 52-week high, following a 124% increase over the past year and 64% revenue growth. Despite this impressive performance and positive investor sentiment reflected in an 8% pre-market increase after Q1 2026 earnings, the company reported a net loss of $1.26 per share and slightly missed revenue expectations. InvestingPro indicates the stock is trading near its Fair Value, although the company remains unprofitable.
Moderna’s mRNA flu shot to get FDA review
Moderna's mRNA flu vaccine candidate, MFLUSIVA, will undergo review by an FDA advisory panel on June 18 after an initial refusal. The FDA is expected to make a decision by August 5, aiming for the next flu season. This decision follows a period of controversy surrounding the vaccine's initial rejection and leadership changes within the FDA.
Flagship Pioneering trades 9,263 Moderna (MRNA) shares via option exercise
Flagship Pioneering, LLC, an entity associated with Moderna director Noubar Afeyan, exercised options to acquire 9,263 Moderna (MRNA) common shares at $19.15 each and subsequently sold all of them on the open market at an average price of $46.84 per share. This transaction, reported on an SEC Form 4 filing, resulted in a net sale of 9,263 shares and leaves Afeyan and related entities with substantial indirect holdings. The options were fully vested and set to expire in August 2026.
Tempest Therapeutics announces resignation of three board members
Tempest Therapeutics (NASDAQ:TPST) announced the resignation of three board members, Stephen Brady, Michael Raab, and Christine Pellizzari, effective May 22, 2026. The company stated there were no disagreements and separation agreements were signed, waiving retainer fees but preserving stock option rights and indemnification agreements. This news follows recent positive clinical trial data for its TPST-2003 CAR-T therapy and a private placement, alongside a Nasdaq deficiency notice due to low stockholders' equity.
BioXcel (BTAI) CFO exercises 17,500 RSUs and sells 6,845 shares for taxes
BioXcel Therapeutics, Inc.'s CFO, Richard Steinhart, exercised 17,500 Restricted Stock Units (RSUs) on May 4, 2026, receiving common shares. On May 20, 2026, he sold 6,845 of these common shares at a weighted average price of $1.085 to cover tax obligations related to the RSU vesting, as per a Rule 10b5-1 trading plan. Following these transactions, Steinhart directly holds 26,300 common shares and 52,500 unvested RSUs.
BioXcel Therapeutics (BTAI) executive sells shares after RSU vesting for taxes
BioXcel Therapeutics executive Javier Rodriguez sold 6,560 shares of Common Stock at an average price of $1.084 per share on May 20, 2026, following the vesting of 17,500 Restricted Stock Units (RSUs) on May 4, 2026. This sale was conducted under a Rule 10b5-1 trading plan to cover tax obligations arising from the RSU vesting. After these transactions, Rodriguez directly holds 26,803 shares of Common Stock and 52,500 RSUs.
Lynozyfic AL Amyloidosis Data Gives Regeneron Pipeline And Valuation Focus
Regeneron Pharmaceuticals reported positive Phase 1/2 data for Lynozyfic (linvoseltamab) in systemic AL amyloidosis, with all patients achieving hematologic responses and organ improvement in those with organ involvement. This news provides a new late-stage asset for investors to monitor within Regeneron's pipeline, especially as detailed results are anticipated at ASCO 2026. The stock is currently trading below analyst targets and an internal fair value estimate, despite the promising clinical data.
Hospitals Take CVS to Court Over Alleged $250M 340B Scheme
Three health systems—Mount Sinai, Michigan Medicine, and the University of Kansas Health System—have filed lawsuits against CVS Health. They allege that CVS's pharmacy benefit manager, CVS Caremark, diverted approximately $250 million in savings from the 340B Drug Pricing Program between 2020 and 2025 through "spread pricing." The hospitals claim these funds were meant to support care for vulnerable patients and are seeking accountability and recovery of the diverted money.
VolitionRx receives waiver on market capitalization covenant from Lind Global
VolitionRx (NYSE:VNRX) has secured a waiver from Lind Global Asset Management XII LLC regarding a market capitalization covenant breach linked to its convertible promissory notes. The company, which has a market capitalization of $24.64 million and $11.7 million in total debt, failed to meet the minimum market capitalization requirement for two notes issued in May 2025 and January 2026. As a result of the waiver, Lind Global will not exercise certain rights and remedies, including immediately calling the notes due, but VolitionRx is required to pay an additional 10% of the outstanding principal on each note.
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are ...
The Rosen Law Firm is investigating potential securities claims against ADMA Biologics, Inc. (NASDAQ: ADMA) on behalf of investors who suffered losses. This investigation follows allegations that ADMA Biologics issued misleading business information, which led to a 16.6% drop in its stock on March 26, 2024, after a short-seller report accused the company of channel stuffing to inflate revenue growth. Investors are encouraged to contact the law firm to learn about their options for recovering losses.
Theravance Biopharma (TBPH) SVP uses 5,678 shares to cover tax bill
Theravance Biopharma SVP Rhonda Farnum disposed of 5,678 Ordinary Shares at $16.55 per share to cover tax obligations related to the vesting of restricted stock units. This was a routine, non-market tax-withholding transaction, not an open-market sale. Following this event, Farnum still directly holds 245,771 Ordinary Shares, maintaining a substantial equity stake in the company.
Trading Systems Reacting to (BHVN) Volatility
This article from Stock Traders Daily analyzes Biohaven Ltd. (NASDAQ: BHVN) volatility, identifying strong near-term sentiment but persistent mid and long-term weakness. It highlights an exceptional 85.7:1 risk-reward setup targeting a 28.0% gain. The piece outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and support/resistance levels.
Casdin discloses 9.7% BioLife Solutions stake (NASDAQ: BLFS)
Casdin Capital and its affiliates have disclosed a 9.7% beneficial ownership stake in BioLife Solutions (NASDAQ: BLFS), totaling 4,757,165 common shares. The stake was acquired for investment purposes using the fund's working capital, without specific borrowing. While currently having no concrete plans for corporate changes, Casdin reserves the right to engage with management and other shareholders to maximize shareholder value and may adjust its holdings in the future.
[Form 4] Roivant Sciences Ltd. Insider Trading Activity
Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), reported insider transactions including exercising stock options for 200,000 common shares at $3.85 and subsequently selling those shares at a weighted average price of $30.27. He also surrendered 34,483 shares for tax withholding on vested RSUs, which was a non-market disposition. After these activities, Venker retains a substantial stake of 1,813,063 common shares, indicating the transactions were compensation- and liquidity-related rather than a reduction in ownership.
Teleflex presents clinical data on UroLift and Barrigel products By Investing.com
Teleflex Incorporated announced new clinical data for its UroLift System and Barrigel rectal spacer at recent medical conferences. The UroLift study showed a significantly lower rate of catheterization compared to a competitor, while the Barrigel study indicated zero percent Grade 2+ toxicity at three years. Despite a planned divestiture of its Interventional Urology unit, Teleflex is expected to maintain profitability and stock value.
Lynozyfic AL Amyloidosis Data Gives Regeneron Pipeline And Valuation Focus
Regeneron Pharmaceuticals reported positive Phase 1/2 data for Lynozyfic (linvoseltamab) in systemic AL amyloidosis, with all patients achieving hematologic responses and improved organ function in those with organ involvement. This data adds a promising late-stage asset to Regeneron's pipeline, which is particularly notable as the stock has been under recent pressure. Investors are now focused on the ongoing registrational Phase 2 study and upcoming detailed results at ASCO 2026.
Director at Option Care Health (OPCH) receives 8,997 RSUs worth $200,000
Option Care Health director Norman L. Wright was granted 8,997 restricted stock units (RSUs) on May 20, 2026, valued at $200,000 based on that day's closing share price. These RSUs will fully vest on May 20, 2027, provided he remains eligible through that date. Following this equity award, Wright directly holds 24,498 shares of the company's common stock.
Option Care Health (OPCH) director granted $200K in RSUs and fee-linked shares
Option Care Health director Eric Brandt was granted equity awards totaling $200,000 in restricted stock units (RSUs) and additional shares as part of his compensation on May 20, 2026. He acquired 2,643 shares of common stock and 8,997 RSUs in lieu of cash retainer payments, all of which will vest fully on May 20, 2027. Following these transactions, Brandt now directly holds 21,999 shares of Option Care Health common stock.
